Masignani Vega, Palacios Ricardo, Martin Marie-Thérèse, Tibaldi Fabian, Vadivelu V Kumaran
GSK, Siena, Italy.
CARB-X, Boston University School of Law, Boston, MA, USA.
NPJ Vaccines. 2025 Jul 30;10(1):177. doi: 10.1038/s41541-025-01211-z.
Vaccine development is long and costly. Technical, clinical, regulatory, and manufacturing risks throughout the development cycle hampered manufacturers' efforts towards more challenging and financially less rewarding targets, with profound implications for public health. Early de-risking strategies can help closing the vaccine productivity gap and support sustainable access to vaccines. Illustrated by examples of early and efficient decision-making, the herein proposed strategies can ultimately increase the success rates of vaccine programs.
疫苗研发周期长且成本高昂。整个研发周期中的技术、临床、监管和生产风险阻碍了制造商朝着更具挑战性且经济回报较低的目标努力，对公共卫生产生了深远影响。早期降低风险策略有助于缩小疫苗生产效率差距，并支持疫苗的可持续获取。通过早期高效决策的实例说明，本文提出的策略最终可提高疫苗项目的成功率。
